Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Baidu Inc (BIDU) vs Heron Therapeutics Inc (HRTX) Price & Performance

Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Baidu Inc vs Heron Therapeutics Inc — how do they compare? Baidu Inc trades at $103.71 (market cap $36.18B), while Heron Therapeutics Inc trades at $0.34 (market cap $61.47M). The key difference: Baidu Inc is far larger — about 588.6× Heron Therapeutics Inc's market cap, and Baidu Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

BIDUHRTX
Market Cap
$36.18B$61.47M
Sector
MediaHealth
52-Week High
$162.52$1.49
52-Week Low
$86.76$0.32
Enterprise Value
$32.81B$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Baidu Inc

Baidu (BIDU) trades at $109.50, down 0.19% on the day, with technicals indicating a bearish trend and key support at $108. The company reported a sharp decline in net income to $5.59 billion in 2025, with margins contracting, though it beat EPS estimates in two of the last three quarters. Recent news highlights autonomous vehicle testing in London and a planned Q2 2026 earnings report on August 18, 2026.

The outlook is mixed: strong analyst buy ratings (75.47%) and a $169.80 price target suggest upside, but bearish technicals, profit margin pressures, and China market risks pose challenges. Investment opportunity hinges on AI and cloud growth offsetting advertising weakness, while risks include execution missteps and regulatory headwinds.

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Baidu Inc

Baidu, Inc. operates an Internet search engine. The Company offers algorithmic search, enterprise search, news, MP3, and image searches, voice assistance, online storage, and navigation services. Baidu serves clients globally.

Read more on BIDU

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX